title: The Health Impact Fund: a potential solution to inequity in global drug access.
abstract: Global health inequities persist despite significant increases in funding and a growing number of global health initiatives. Especially vulnerable to disease, the poor majority of the world's population currently cannot afford advanced medicines, and the diseases confined to the poor receive little attention from pharmaceutical research. As a complement to the existing intellectual property regime, we have proposed the Health Impact Fund (HIF) as a mechanism that would create incentives for the development and optimal promotion of new high-impact medicines sold at the cost of manufacture. In this article, we outline the HIF and its ethical significance.
authors: Stroke Prevention Research Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom. amitava.banerjee@clneuro.ox.ac.uk
authors: Amitava
authors: A
authors: Banerjee
authors: Thomas
authors: T
authors: Pogge
mesh_terms: D055808:Drug Discovery / Q000191:economics / Q000941:ethics; D004345:Drug Industry / Q000191:economics*; D005252:Fees, Pharmaceutical / Q000941:ethics; D005380:Financing, Government; D014943:Global Health; D006297:Health Services Accessibility / Q000191:economics*; D054625:Healthcare Disparities / Q000941:ethics; D006801:Humans; D007391:International Cooperation; D009965:Orphan Drug Production / Q000191:economics / Q000941:ethics; D010330:Patents as Topic / Q000941:ethics / Q000331:legislation & jurisprudence; D012109:Research Support as Topic / Q000458:organization & administration